Ravit Boger, MD

Publications

• Genomic Markers Associated with Cytomegalovirus DNAemia in Kidney Transplant Recipients.

  (Shapira G, Volkov H, Fabian I, Mohr DW, Bettinotti M, Shomron N, Avery RK, Arav-Boger R.) Viruses. 2023 Nov 08;15(11) PMID: 38005904 11/25/2023

• Harnessing the Noncanonical Keap1-Nrf2 Pathway for Human Cytomegalovirus Control.

  (Ghosh AK, Su YP, Forman M, Keyes RF, Smith BC, Hu X, Ferrer M, Arav-Boger R.) J Virol. 2023 Apr 27;97(4):e0016023 PMID: 36939350 PMCID: PMC10134830 SCOPUS ID: 2-s2.0-85159161803 03/21/2023

• Correction: Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization.

  (Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R.) Clin Cancer Res. 2022 Apr 14;28(8):1737 PMID: 35419593 SCOPUS ID: 2-s2.0-85128329131 04/15/2022

• The Synthesis and Anti-Cytomegalovirus Activity of Piperidine-4-Carboxamides.

  (Guo X, Ghosh AK, Keyes RF, Peterson F, Forman M, Meyers DJ, Arav-Boger R.) Viruses. 2022 Jan 25;14(2) PMID: 35215828 PMCID: PMC8876412 SCOPUS ID: 2-s2.0-85123542102 02/27/2022

• The Synthesis and Anti-Cytomegalovirus Activity of Piperidine-4-Carboxamides

  (Guo X, Ghosh AK, Keyes RF, Peterson F, Forman M, Meyers DJ, Arav-Boger R.) Viruses. February 2022;14(2) SCOPUS ID: 2-s2.0-85123542102 02/01/2022

• T cell receptor-targeted immunotherapeutics drive selective in vivo HIV- and CMV-specific T cell expansion in humanized mice.

  (Li M, Garforth SJ, O'Connor KE, Su H, Lee DM, Celikgil A, Chaparro RJ, Seidel RD, Jones RB, Arav-Boger R, Almo SC, Goldstein H.) J Clin Invest. 2021 Dec 01;131(23) PMID: 34673568 PMCID: PMC8631598 SCOPUS ID: 2-s2.0-85121153546 10/22/2021

• A Novel Multiplexed Enzyme-Linked Immunosorbent Assay for the Detection of IgG Seroreactivity to Cytomegalovirus (CMV) UL144.

  (Miller H, Simpson P, Forman M, Prigan A, Kehl S, Mesich B, Faron M, Ledeboer N, Arav-Boger R.) J Clin Microbiol. 2021 Jul 19;59(8):e0096421 PMID: 34076473 PMCID: PMC8373222 SCOPUS ID: 2-s2.0-85112127278 06/03/2021

• Inhibition of Human Coronaviruses by Antimalarial Peroxides.

  (Ghosh AK, Miller H, Knox K, Kundu M, Henrickson KJ, Arav-Boger R.) ACS Infect Dis. 2021 Jul 09;7(7):1985-1995 PMID: 33783182 SCOPUS ID: 2-s2.0-85105043981 03/31/2021

• Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.

  (Mehta Steinke SA, Alfares M, Valsamakis A, Shoham S, Arav-Boger R, Lees L, Ostrander D, Forman MS, Shedeck A, Ambinder RF, Jones RJ, Avery RK.) Transpl Infect Dis. 2021 Jun;23(3):e13521 PMID: 33220125 PMCID: PMC9353742 SCOPUS ID: 2-s2.0-85097027320 11/22/2020

• Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition.

  (Roy S, Kapoor A, Zhu F, Mukhopadhyay R, Ghosh AK, Lee H, Mazzone J, Posner GH, Arav-Boger R.) J Biol Chem. 2020 Oct 30;295(44):15013-15028 PMID: 32855235 PMCID: PMC7606667 SCOPUS ID: 2-s2.0-85094983683 08/29/2020

• Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus.

  (Kapoor A, Ghosh AK, Forman M, Hu X, Ye W, Southall N, Marugan J, Keyes RF, Smith BC, Meyers DJ, Ferrer M, Arav-Boger R.) J Med Chem. 2020 Apr 23;63(8):3896-3907 PMID: 32191456 PMCID: PMC7386824 SCOPUS ID: 2-s2.0-85084027851 03/20/2020

• Antiviral Effects of Oleandrin.

  (Newman RA, Sastry KJ, Arav-Boger R, Cai H, Matos R, Harrod R.) J Exp Pharmacol. 2020;12:503-515 PMID: 33262663 PMCID: PMC7686471 12/03/2020